Hachida M, Zhang X L, Lu H, Hoshi H, Koyanagi H
Department of Cardiovascular Surgery, Heart Institute of Japan, Tokyo Women's Medical College.
Transplantation. 1998 Jun 15;65(11):1446-50. doi: 10.1097/00007890-199806150-00006.
Graft coronary arteriosclerosis (GCA) is the major limiting factor for long-term survival after heart transplantation. In this study, we investigated the effect of Multiglycosidorum tripterygii (MT) on GCA and platelet-derived growth factor A (PDGF-A) mRNA expression of transplanted hearts.
Two groups of Lewis rats (n=7/group) underwent heterotopic heart transplantation from Wistar-King donors and were treated with either cyclosporine (CsA;10 mg/kg/day) or MT (30 mg/kg/ day). Histological evaluations of rejection and coronary arteriosclerosis, as well as Northern blot analysis on graft PDGF-A mRNA expression were made 60 days after transplantation.
Morphometric results indicated no significant difference in rejection between the CsA- and MT-treated groups. However, the extent of GCA in the MT-treated group was significantly less than that seen in the CsA-treated group (P<0.01). The expression of PDGF-A mRNA of cardiac allograft was also significantly suppressed in the MT-treated group when compared with the CsA-treated group (P<0.01).
MT is superior to CsA in preventing graft coronary arteriosclerosis, and this efficacy is probably associated with the depressed expression of graft PDGF-A mRNA in the MT-treated group.
移植冠状动脉粥样硬化（GCA）是心脏移植后长期存活的主要限制因素。在本研究中，我们调查了雷公藤多苷（MT）对移植心脏GCA及血小板衍生生长因子A（PDGF-A）mRNA表达的影响。
两组Lewis大鼠（每组n = 7）接受来自Wistar-King供体的异位心脏移植，并分别用环孢素（CsA；10 mg/kg/天）或MT（30 mg/kg/天）治疗。移植后60天进行排斥反应和冠状动脉粥样硬化的组织学评估，以及对移植心脏PDGF-A mRNA表达的Northern印迹分析。
形态学结果表明，CsA治疗组和MT治疗组之间在排斥反应方面无显著差异。然而，MT治疗组的GCA程度明显低于CsA治疗组（P < 0.01）。与CsA治疗组相比，MT治疗组同种异体心脏移植中PDGF-A mRNA的表达也明显受到抑制（P < 0.01）。
在预防移植冠状动脉粥样硬化方面，MT优于CsA，这种疗效可能与MT治疗组中移植心脏PDGF-A mRNA表达降低有关。
